Blog
RSS FeedPosted by Michael Wonder on 22 Dec 2023
Keytruda (pembrolizumab) plus Lenvima (lenvatinib) receive public listing for patients with advanced endometrial carcinoma that is not MSI-H or dMMR
21 December 2023 - Merck and Eisai announce that Keytruda plus Lenvima, is now reimbursed with clinical criteria and conditions ...
Posted by Michael Wonder on 26 Oct 2023
Keytruda (pembrolizumab) plus Lenvima (lenvatinib) is available for the first-line treatment of adult patients with advanced or metastatic renal cell carcinoma
25 October 2023 - Merck and Eisai announced today that Keytruda, an anti-PD-1 therapy, in combination with Lenvima, the multiple receptor ...
Posted by Michael Wonder on 30 Sep 2023
Medison Pharma announces public formulary listing of Qinlock (ripretinib) in Canadian provinces: Ontario and Quebec for advanced gastro-intestinal stromal tumour treatment
29 September 2023 - Medison Pharma is pleased to announce the public formulary listing of Qinlock in Canadian provinces: Ontario ...
Posted by Michael Wonder on 08 Mar 2023
Jazz Pharmaceuticals secures eight additional provincial reimbursements for Vyxeos for treatment of adults with newly diagnosed therapy-related acute myeloid leukaemia or acute myeloid leukaemia with myelodysplasia-related changes
8 March 2023 - Jazz Pharmaceuticals announced today that Vyxeos (daunorubicin and cytarabine liposome for injection) is now included on eight ...
Posted by Michael Wonder on 21 Apr 2022
Astellas announces reimbursement for Xospata (gilteritinib) in most provinces for patients with relapsed or refractory acute myeloid leukaemia with a FLT3 mutation
21 April 2022 - Having access to an additional treatment option offers hope for Canadian adult AML patients with relapsed ...
Posted by Michael Wonder on 12 Oct 2020
Radiopharmaceutical cancer treatment Lutathera now available to Ontario patients with midgut neuroendocrine tumours
8 October 2020 - Lutathera is the first and only therapeutic radiopharmaceutical approved by Health Canada for the treatment of GEP-NETs. ...
Posted by Michael Wonder on 13 Sep 2019
Medexus reports Health Quality Ontario recommends Gliolan for public reimbursement
12 September 2019 - Medexus Pharmaceuticals today announced that Health Quality Ontario, under the guidance of the Ontario Health Technology ...
Posted by Michael Wonder on 02 May 2018
Ontario NDP promise take-home cancer drug coverage ahead of election
30 April 2018 - NDP Leader Andrea Horwath is promising universal access to take-home cancer drugs if her party wins ...
Posted by Michael Wonder on 07 Mar 2017
Ontario cancer patient 'in limbo' over chemotherapy drug shortage
7 March 2017 - A cancer patient who was told last week that she may not receive her much-needed chemotherapy ...